Registry to assess heart function in patients with atrial fibrillation
EARLY-MYO-AF (EARLY Integrated Therapies on MYOcardial Function Improvements in Patients With Atrial Fibrillation) Registry
This study is trying to see how different treatments for atrial fibrillation can improve heart function in patients over a period of up to three years.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 5000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | RenJi Hospital Academic / other |
| Locations | 1 site (Shanghai, Shanghai) |
| Trial ID | NCT04512222 on ClinicalTrials.gov |
What this trial studies
This observational registry aims to evaluate improvements in myocardial function among patients with atrial fibrillation (AF) through integrated therapies. It will collect data from approximately 5000 AF patients who undergo various interventions, including radio-frequency catheter ablation and left atrial appendage occlusion, over a follow-up period of up to 3 years. The study will analyze the pathophysiological changes in both atrial and ventricular function and identify clinical factors associated with adverse outcomes. The goal is to establish a comprehensive understanding of AF management and potential therapeutic targets.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who are clinically indicated for catheter ablation or other interventions for persistent or long-standing persistent atrial fibrillation.
Not a fit: Patients who have contraindications for anticoagulation therapy or a life expectancy of less than 6 months may not benefit from this study.
Why it matters
Potential benefit: If successful, this registry could lead to improved treatment strategies and better clinical outcomes for patients with atrial fibrillation.
How similar studies have performed: Other studies have shown success in similar observational approaches, indicating the potential for valuable insights into atrial fibrillation management.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Eligible patients must be at least 18 years old at the time of enrollment. * Patients who are clinically indicated catheter ablation or other interventions (LAAC or surgical maze procedure) for persistent or long standing persistent AF. Exclusion Criteria: * Contraindication for anticoagulation therapy * Another (non-AF) indication for long term anticoagulation * Patients who have been enrolled as a respondent on other clinical studies * Inability to attend scheduled, periodic office visits for follow-up * Pregnancy * Patient has a life expectancy of less than 6 months due to any condition.
Where this trial is running
Shanghai, Shanghai
- Ren Ji Hospital Affliated to School of Medicine, Shanghai Jiao Tong University — Shanghai, Shanghai, China (Recruiting)
Study contacts
- Study coordinator: Lingcong Kong, M.D.
- Email: avrilblanche373@126.com
- Phone: 008602168383164
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.